What it is

Sermorelin is a synthetic peptide corresponding to a shortened fragment of human GHRH, commonly described as GHRH(1–29). It is intended to stimulate pituitary GH release via the GHRH receptor.

Sermorelin is not currently marketed as an FDA-approved drug product for long-term therapeutic use in the way many consumers assume. Discussion in wellness contexts often exceeds the strength of clinical evidence for broad outcomes.

Why people use it

It is used with the intention of increasing endogenous GH secretion for symptoms attributed to “low GH,” body composition, or “anti-aging” goals. In clinical endocrinology, evaluation of true adult GH deficiency is specialized, and symptom-driven empiric use is not the same as treating a diagnosed deficiency.

History and origin

Sermorelin was developed as a GHRH fragment with pharmacologic activity, reflecting the broader scientific identification and characterization of GHRH and the therapeutic interest in stimulating endogenous GH rather than administering GH itself.

How it works

Sermorelin activates the GHRH receptor on pituitary somatotrophs, increasing GH release and downstream IGF-1 signaling. Physiologic GH secretion remains pulsatile and is constrained by somatostatin, sleep, nutrition, and feedback loops, so the biologic response varies across individuals.

Evidence landscape

Much of the sermorelin-specific literature is older, mixed in scope, and often focused on diagnostic endocrinology or pediatric contexts rather than broad adult wellness outcomes. Modern marketing claims are frequently not matched by contemporary, well-powered randomized trials with patient-important endpoints.

Safety reality

Potential adverse effects include injection-site reactions and endocrine-related effects if GH/IGF-1 rises meaningfully. In practice, risk also depends on whether products are compounded or sourced from non-regulated suppliers, with attendant purity and identity concerns.

References

Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of GH secretion (1993). https://pubmed.ncbi.nlm.nih.gov/8329825/

Growth response to GHRH(1-29)-NH2 compared with growth hormone (1993). https://pubmed.ncbi.nlm.nih.gov/8329826/

GH profiles in response to continuous SC infusion of GHRH(1-29)-NH2 (1993). https://pubmed.ncbi.nlm.nih.gov/8329829/